A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2018
At a glance
- Drugs ABBV 368 (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Non-small cell lung cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 27 Jul 2018 Planned number of patients changed from 100 to 150.
- 27 Jul 2018 Planned End Date changed from 26 Feb 2020 to 8 Jul 2020.
- 28 Feb 2018 Planned End Date changed from 16 Oct 2019 to 26 Feb 2020.